The world’s first approved antibody-drug conjugate ... acute myeloid leukaemia patients whose tumours express the CD33 antigen, and adults and children two years and older with relapsed or ...

The drug is based on an antibody component targeting the CD33 receptor linked to a molecule that breaks down GSPT1, an intracellular protein that is thought to promote the proliferation ...